Stem Cell Recruitment in Osteoporosis Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01656629
Recruitment Status : Active, not recruiting
First Posted : August 3, 2012
Last Update Posted : May 9, 2018
Information provided by (Responsible Party):
Johns Hopkins University

Brief Summary:
Osteoporosis is an important health problem in the rapidly-aging demographic. Fragility fractures are devastating consequences of osteoporosis. The most common treatment approach in osteoporosis is inhibition of bone resorption with drugs like alendronate (ALN). Parathyroid hormone (PTH) stimulates bone formation and is the only anabolic drug available. Dual therapy with ALN and PTH is not as effective as single-drug therapy in preventing fracture. Bone progenitor cells (MSCs) are recruited to sites of bone remodeling when a growth factor called Transforming Growth Factor Beta (TGF-β1) is released from bone. Different osteoporosis medicines may have differing effects on this process. The effects of ALN versus PTH on bone progenitor recruitment in humans are unknown. This is a randomized, clinical trial of ALN, PTH, and calcium and vitamin D in post-menopausal women with low bone mass. Women will be treated for 3 months with ALN or PTH or calcium and vitamin D. Data collected will include bone biopsies for histomorphometry and micro computed tomography (µCT), bone marrow aspirates for molecular studies, peripheral blood to detect circulating bone progenitor cells and dual X-ray absorptiometry. The investigators hypothesize that in humans, PTH will 1) increase bone progenitor number, 2) enhance recruitment of bone progenitor cells to bone resorption sites, and 3) increase bone progenitor number in peripheral circulation. Furthermore, the investigators hypothesize that ALN treatment will have the opposite effect. Understanding the differences in bone progenitor cell activity and recruitment during osteoporosis therapy will provide a mechanistic rationale for effective use of PTH and anti-resorptive drugs in osteoporosis treatment.

Condition or disease Intervention/treatment Phase
Low Bone Density Drug: Teriparatide Drug: Alendronate Dietary Supplement: calcium and vitamin D Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 46 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Stem Cell Recruitment in Osteoporosis Therapy
Actual Study Start Date : August 2012
Estimated Primary Completion Date : August 2019
Estimated Study Completion Date : August 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: teriparatide
teriparatide 20 mcg sq for 3 months
Drug: Teriparatide
20 mcg subq daily for 3 months

Active Comparator: Alendronate
70 mg po weekly for 3 months
Drug: Alendronate
70 mg weekly for 3 months

Active Comparator: calcium and vitamin D
calcium 630 mg vitamin D 500 units daily for 3 months
Dietary Supplement: calcium and vitamin D

Primary Outcome Measures :
  1. The percent change in circulating osteoprogenitor cells as assessed by flow cytometry in the blood before and after treatment with PTH or ALN. [ Time Frame: up to 3 months ]

Secondary Outcome Measures :
  1. Difference in bone formation as assessed by bone histomorphometry on bone biopsy between treatment groups [ Time Frame: 3 months ]
  2. Difference in osteogenic potential of bone marrow as measure by colony forming unit osteoblast (CFU-Ob) assays between treatment groups [ Time Frame: 3 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   50 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Post-menopausal women aged 50-80 years
  • T score < -2.5 at lumbar spine, total hip or femoral neck on dual x-ray absorptiometry (DXA) OR T score < -1.5 with a personal or family history of fracture

Exclusion Criteria:

  • Previous use of bisphosphonates or Teriparatide; current estrogen therapy; any other osteoporosis therapy in the past 6 months
  • Metabolic bone disease other than osteoporosis
  • Body mass index (BMI) < 18
  • Weight > 325 lbs
  • Current smoking or current alcohol use that exceeds 3 units of alcohol daily
  • Use of medications known to affect bone metabolism
  • Renal disease, history of kidney stones or hypercalciuria
  • Hypo- or hyperparathyroidism; hypo- or hypercalcemia
  • Serum vitamin D level < 20 ng/dL
  • Refusal to adjust their dietary calcium to <750mg (i.e. two servings per day of calcium rich food)
  • History of bone marrow or organ transplant
  • History of malignancy or radiation to the bone
  • History of esophageal stricture, dysmotility or severe reflux disease
  • Gastrointestinal malabsorption
  • Use of digoxin
  • Need for chronic anticoagulation therapy such as Coumadin, heparin or low molecular weight heparin or inability to discontinue anti-platelet medication
  • Bleeding diathesis; hemoglobin ≤ 12.5 g/dL (American Red Cross cut-off to donate blood)
  • International normalized ratio (INR) pro time > 1.1 or activated partial thromboplastin time (APT) T ratio > 1.2
  • Platelets < 150K/cu mm
  • Cellulitis at site of iliac crest
  • History of allergy to medications used in bone biopsy (demeclocycline, lidocaine)
  • Inability to understand and provide informed consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01656629

United States, Maryland
Johns Hopkins Bayview Medical Center
Baltimore, Maryland, United States, 21224
Sponsors and Collaborators
Johns Hopkins University
Principal Investigator: Suzanne Jan De Beur, MD Johns Hopkins University

Responsible Party: Johns Hopkins University Identifier: NCT01656629     History of Changes
Other Study ID Numbers: NA_00050448
First Posted: August 3, 2012    Key Record Dates
Last Update Posted: May 9, 2018
Last Verified: May 2018

Additional relevant MeSH terms:
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Metabolic Diseases
Vitamin D
Calcium, Dietary
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents